Dasatinib, originally developed for the treatment of chronic myelogenous leukemia (CML), is not only an inhibitor of BCR-ABL but also a potent inhibitor of SFKs [47]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.